{"id":63232,"date":"2026-04-15T21:37:31","date_gmt":"2026-04-15T13:37:31","guid":{"rendered":"https:\/\/flcube.com\/?p=63232"},"modified":"2026-04-15T21:37:33","modified_gmt":"2026-04-15T13:37:33","slug":"huadong-medicines-semaglutide-biosimilar-hdm1702-enters-nmpa-review-for-weight-management-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63232","title":{"rendered":"Huadong Medicine&#8217;s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted for review its <strong>marketing application<\/strong> for <strong>HDM1702<\/strong>, a biosimilar version of <strong>Novo Nordisk&#8217;s<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) <strong>semaglutide<\/strong>, for <strong>long-term weight management<\/strong> in adult patients with obesity or overweight with comorbidities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Huadong Medicine Co., Ltd. (SHE: 000963)<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Novo Nordisk&#8217;s semaglutide (Wegovy\/Ozempic)<\/td><\/tr><tr><td><strong>Biosimilar Candidate<\/strong><\/td><td>HDM1702<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Status<\/strong><\/td><td>Accepted for formal review<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Long-term weight management<\/td><\/tr><tr><td><strong>Secondary Application<\/strong><\/td><td>Type 2 diabetes (also under NMPA review)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-population-amp-indication-details\">Target Population &amp; Indication Details<\/h2>\n\n\n\n<p>The sought-after indication covers adult patients meeting specific criteria:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity<\/strong>: BMI \u226530 kg\/m\u00b2<\/li>\n\n\n\n<li><strong>Overweight with Comorbidities<\/strong>: BMI \u226527 kg\/m\u00b2 to &lt;30 kg\/m\u00b2 with at least one weight-related condition:<\/li>\n\n\n\n<li>Hyperglycemia<\/li>\n\n\n\n<li>Hypertension<\/li>\n\n\n\n<li>Dyslipidemia<\/li>\n\n\n\n<li>Obstructive sleep apnea<\/li>\n\n\n\n<li>Cardiovascular disease<\/li>\n<\/ul>\n\n\n\n<p>Treatment is intended as an <strong>adjunct to reduced-calorie diet and increased physical activity<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-development-background\">Drug Profile &amp; Development Background<\/h2>\n\n\n\n<p><strong>Semaglutide<\/strong> is a <strong>long-acting glucagon-like peptide-1 (GLP-1) receptor agonist<\/strong> with established global regulatory history:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diabetes Approval Timeline<\/strong>:<\/li>\n\n\n\n<li>US: 2017 (Ozempic)<\/li>\n\n\n\n<li>EU: 2018<\/li>\n\n\n\n<li>China: 2021<\/li>\n\n\n\n<li><strong>Weight Management Approval Timeline<\/strong>:<\/li>\n\n\n\n<li>US: 2021 (Wegovy)<\/li>\n\n\n\n<li>EU: 2022<\/li>\n\n\n\n<li>China: 2024<\/li>\n<\/ul>\n\n\n\n<p><strong>HDM1702<\/strong> has demonstrated <strong>comparable safety and efficacy<\/strong> to the originator product in Chinese subjects with obesity, supporting its biosimilar designation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-analysis\">Market Opportunity Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Explosive Demand<\/strong>: GLP-1 receptor agonists represent one of the fastest-growing pharmaceutical categories globally<\/li>\n\n\n\n<li><strong>Chinese Market Potential<\/strong>: With over 50% of Chinese adults overweight or obese, the addressable population exceeds 600 million people<\/li>\n\n\n\n<li><strong>Cost Accessibility<\/strong>: Biosimilar pricing could significantly improve access compared to premium-priced originator products<\/li>\n\n\n\n<li><strong>Dual Indication Strategy<\/strong>: Simultaneous pursuit of diabetes and weight management indications maximizes commercial potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<p>The Chinese GLP-1 biosimilar market is becoming increasingly competitive, with multiple domestic companies pursuing similar development programs. Key success factors include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory First-Mover Advantage<\/strong>: Early approval could capture significant market share before competitors<\/li>\n\n\n\n<li><strong>Manufacturing Scale<\/strong>: Ability to meet anticipated high-volume demand<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Established relationships with endocrinologists and primary care physicians<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Optimal balance between market penetration and profitability<\/li>\n<\/ul>\n\n\n\n<p>Huadong Medicine&#8217;s dual-track approach\u2014pursuing both diabetes and weight management indications simultaneously\u2014positions the company to potentially become a dominant player in China&#8217;s GLP-1 market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification<\/strong>: Expands Huadong&#8217;s presence beyond traditional pharmaceuticals into high-growth metabolic disease therapeutics<\/li>\n\n\n\n<li><strong>Revenue Growth<\/strong>: GLP-1 biosimilars represent multi-billion dollar revenue opportunities in China alone<\/li>\n\n\n\n<li><strong>Healthcare Impact<\/strong>: Improved access to effective weight management therapies addresses critical public health challenges<\/li>\n\n\n\n<li><strong>Global Ambitions<\/strong>: Success in China could support future international regulatory submissions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>China&#8217;s regulatory pathway for complex biologics like GLP-1 receptor agonists has matured significantly, enabling domestic companies to develop high-quality biosimilars that meet international standards. The acceptance of HDM1702&#8217;s marketing application represents a significant milestone in China&#8217;s evolution from generic manufacturer to innovative biosimilar developer.<\/p>\n\n\n\n<p>If approved, HDM1702 would provide Chinese patients and healthcare providers with a domestically produced, cost-effective alternative to imported GLP-1 therapies, potentially transforming the standard of care for obesity and type 2 diabetes management.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial opportunities for HDM1702. Actual results may differ due to risks including regulatory decisions, manufacturing challenges, competitive dynamics, and market adoption rates in China&#8217;s rapidly evolving GLP-1 therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4361,114,38,148,860,86,887],"class_list":["post-63232","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hot-targets","tag-huadong-medicine","tag-market-approval-filings","tag-novo-nordisk","tag-nyse-nvo","tag-obesity","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine&#039;s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing application for HDM1702, a biosimilar version of Novo Nordisk&#039;s (NYSE: NVO) semaglutide, for long-term weight management in adult patients with obesity or overweight with comorbidities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63232\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine&#039;s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing application for HDM1702, a biosimilar version of Novo Nordisk&#039;s (NYSE: NVO) semaglutide, for long-term weight management in adult patients with obesity or overweight with comorbidities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63232\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T13:37:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T13:37:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63232#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63232\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine&#8217;s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication\",\"datePublished\":\"2026-04-15T13:37:31+00:00\",\"dateModified\":\"2026-04-15T13:37:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63232\"},\"wordCount\":541,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Hot targets\",\"Huadong Medicine\",\"Market approval filings\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63232#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63232\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63232\",\"name\":\"Huadong Medicine's Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-15T13:37:31+00:00\",\"dateModified\":\"2026-04-15T13:37:33+00:00\",\"description\":\"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing application for HDM1702, a biosimilar version of Novo Nordisk's (NYSE: NVO) semaglutide, for long-term weight management in adult patients with obesity or overweight with comorbidities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63232#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63232\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63232#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine&#8217;s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine's Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing application for HDM1702, a biosimilar version of Novo Nordisk's (NYSE: NVO) semaglutide, for long-term weight management in adult patients with obesity or overweight with comorbidities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63232","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine's Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication","og_description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing application for HDM1702, a biosimilar version of Novo Nordisk's (NYSE: NVO) semaglutide, for long-term weight management in adult patients with obesity or overweight with comorbidities.","og_url":"https:\/\/flcube.com\/?p=63232","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T13:37:31+00:00","article_modified_time":"2026-04-15T13:37:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63232#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63232"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine&#8217;s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication","datePublished":"2026-04-15T13:37:31+00:00","dateModified":"2026-04-15T13:37:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63232"},"wordCount":541,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Hot targets","Huadong Medicine","Market approval filings","Novo Nordisk","NYSE: NVO","Obesity","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63232#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63232","url":"https:\/\/flcube.com\/?p=63232","name":"Huadong Medicine's Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-15T13:37:31+00:00","dateModified":"2026-04-15T13:37:33+00:00","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing application for HDM1702, a biosimilar version of Novo Nordisk's (NYSE: NVO) semaglutide, for long-term weight management in adult patients with obesity or overweight with comorbidities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63232#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63232"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63232#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine&#8217;s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63232"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63232\/revisions"}],"predecessor-version":[{"id":63233,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63232\/revisions\/63233"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}